Home Companies Catalysts Deep Dives
Vyvanse lisdexamfetamine APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2007-02-23
US LOE2023-08-24
Peak Sales Est$3000M
Formulations[{"id":"vyvanse-cap","doses":"10-70mg","route":"PO","setting":"OUTPATIENT","frequency":"Once daily",
Companies
TAK (ORIGINATOR)100%
Mechanism: Prodrug CNS stimulant
Expert: Prodrug of dextroamphetamine, providing extended duration of action and reduced abuse potential.
Everyday: Converted in the body to a stimulant that improves focus and attention.
Targets: []
Revenue History
PeriodRevenue ($M)
2024$2,320M
Q1 2025$382M
Programs (1)
IndicationStageKey StudyRegional Status
ADHDAPPROVEDMultiple Phase 3[{"stage":"APPROVED","region":"US","approval_date":"2007-02-23"}]
Notes
Once top-selling ADHD medication. Facing steep generic erosion. US revenue down ~60% in 2025. Marketed as Elvanse in EU. Last year of major generic impact.
Data from Supabase · Updated 2026-03-24